IRIS
PALA, Daniele
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 1.139
NA - Nord America 1.021
AS - Asia 549
AF - Africa 22
SA - Sud America 2
Totale 2.733
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.017
CN - Cina 376
FI - Finlandia 302
IE - Irlanda 244
IT - Italia 212
SE - Svezia 203
DE - Germania 100
SG - Singapore 83
TR - Turchia 71
FR - Francia 29
CI - Costa d'Avorio 22
BE - Belgio 16
UA - Ucraina 16
IN - India 11
GB - Regno Unito 7
CA - Canada 4
CZ - Repubblica Ceca 3
HU - Ungheria 3
BR - Brasile 2
HK - Hong Kong 2
JP - Giappone 2
NL - Olanda 2
AT - Austria 1
IQ - Iraq 1
MY - Malesia 1
PK - Pakistan 1
RO - Romania 1
TW - Taiwan 1
Totale 2.733
Salva come PNG Salva come JPEG
Città #
Dublin 244
Chandler 238
Parma 122
Beijing 86
Dearborn 82
Izmir 71
Ann Arbor 66
Ashburn 63
Nanjing 63
Singapore 62
Boardman 52
Shanghai 48
Bremen 42
Princeton 42
Jacksonville 38
Wilmington 35
New York 24
Abidjan 22
Helsinki 21
San Mateo 19
Shenyang 18
Kunming 17
Düsseldorf 15
Hebei 15
Brussels 14
Hefei 14
Nanchang 14
Jiaxing 11
Jinan 11
Los Angeles 10
Seattle 10
Guangzhou 9
Hangzhou 9
Changsha 8
Munich 8
Dallas 7
Norwalk 7
Santa Clara 7
Woodbridge 7
Modena 6
Fremont 5
Grafing 5
Pune 5
Rome 5
Zhengzhou 5
Borås 4
Brescia 4
Haikou 4
Hyderabad 4
Milan 4
Springfield 4
Taizhou 4
Tianjin 4
Toronto 4
Fuzhou 3
Bologna 2
Brno 2
Caorso 2
Des Moines 2
Ha Kwai Chung 2
London 2
Marano sul Panaro 2
Palermo 2
Rimini 2
Sant'ilario D'enza 2
Simi Valley 2
Trezzano Sul Naviglio 2
Trieste 2
Washington 2
Amherst 1
Atlanta 1
Auburn Hills 1
Caen 1
Charlottesville 1
Chongqing 1
Cremona 1
Dalian 1
Erlangen 1
Fairfield 1
Frontone 1
Houston 1
La Villa 1
Leipzig 1
Lissone 1
Louvain 1
Magdeburg 1
Mantin 1
Miami 1
Nashville 1
New Delhi 1
New Haven 1
Noceto 1
Orange 1
Pavia 1
Poggio Renatico 1
Porto Alegre 1
Shaoxing 1
Stockholm 1
Tokyo 1
Tulsa 1
Totale 1.780
Salva come PNG Salva come JPEG
Nome #
Inhibition of Eph/ephrin interaction with the small molecule UniPR500 improves glucose tolerance in healthy and insulin-resistant mice 154
UniPR129 is a competitive small molecule Eph-ephrin antagonist blocking in vitro angiogenesis at low micromolar concentrations. 134
Dibasic biphenyl H(3) receptor antagonists: Steric tolerance for a lipophilic side chain. 108
Development of an orally bioavailable small molecule targeting Eph-ephrin system: in vitro and in vivo anticancer activity. 108
Combining ligand- and structure-based approaches for the discovery of new inhibitors of the EPHA2-ephrin-A1 interaction 101
Design and structure-activity relationship of amino acid derivatives of lithocholic acid as novel EphA2 antagonists 92
Amino acid conjugates of lithocholic acid as antagonists of the EphA2 receptor. 83
Discovery and development of Eph-ephrin antagonists endowed with antiangiogenic properties 83
Toward the Definition of Stereochemical Requirements for MT(2)-Selective Antagonists and Partial Agonists by Studying 4-Phenyl-2-propionamidotetralin Derivatives. 79
Multiple approaches for the discovery and development of small molecules targeting Eph-ephrin protein-protein interaction 79
Development of 3-oxo-cholenic derivatives as Eph antagonists able to block in vitro angiogenesis 77
Metadynamics for perspective drug design: Computationally driven synthesis of new protein-protein interaction inhibitors targeting the EphA2 receptor 77
Design and structure-activity relationships of amino acid derivatives of lithocholic acid as novel EphA2 receptor antagonists. 75
Combining pharmacology, target hopping and computational medicinal chemistry to discover novel scaffold targeting EPH-ephrin interaction. 74
Comparative Analysis of Virtual Screening Approaches in the Search for Novel EphA2 Receptor Antagonists 72
Target Hopping as a Useful Tool for the Identification of Novel EphA2 Protein–Protein Antagonists 71
Discovery and development of low molecular weight Eph-ephrin protein-protein inhbi-tors endowed with antiangiogenic activity 70
270 Discovery, development and optimization of low molecular weight EPH–ephrin protein–protein inhibitors 69
Atropisomerism and Conformational Equilibria: Impact on PI3Kδ Inhibition of 2-((6-Amino-9H-purin-9-yl)methyl)-5-methyl-3-(o-tolyl)quinazolin-4(3H)-one (IC87114) and Its Conformationally Restricted Analogs 68
Biochemical characterization of EphA2 antagonists with improved physico-chemical properties by cell-based assays and surface plasmon resonance analysis 67
Δ5-Cholenoyl-amino acids as selective and orally available antagonists of the Eph-ephrin system 66
Exploiting Free-Energy Minima to Design Novel EphA2 Protein-Protein Antagonists: From Simulation to Experiment and Return 64
Metadynamics Simulations Distinguish Short- and Long-Residence-Time Inhibitors of Cyclin-Dependent Kinase 8. 64
Complex product composition generates risks for generic substitution also with dosage forms for intravenous administration 58
Synthesis and Structure-Activity Relationships of Amino Acid Conjugates of Cholanic Acid as Antagonists of the EphA2 Receptor. 57
In vitro and in vivo efficacy of an orally bioavailable antagonist of Eph-ephrin system in tumor angiogenesis and growth 55
Target-hopping: a useful approach to identify novel Eph receptor antagonists 53
Free-energy studies reveal a possible mechanism for oxidation-dependent inhibition of MGL 53
Recent advances in the development of melatonin MT(1) and MT(2) receptor agonists. 52
Computer-Aided Design of Novel Antagonists of the EphA2 Receptor 52
ST7612AA1, a thioacetate-ω(γ-lactam carboxamide) derivative selected from a novel generation of oral HDAC inhibitors 52
Highly Potent and Selective MT2 Melatonin Receptor Full Agonists from Conformational Analysis of 1-Benzyl-2-acylaminomethyl-tetrahydroquinolines 50
Synthesis and characterization of new bivalent agents as melatonin- and histamine h3-ligands. 48
Synthesis of (E)-8-(3-chlorostyryl)caffeine analogs leading to 9-deazaxanthine derivatives as dual A2A antagonists /MAO-B inhibitors. 46
Synthesis, structure and inhibitory activity of a stereoisomer of oseltamivir carboxylate 46
Homology models of melatonin receptors: challenges and recent advances. 46
New classes of potent heparanase inhibitors from ligand-based virtual screening 46
Towards the development of 5-HT7 ligands combining serotonin-like and arylpiperazine moieties 39
Therapeutic uses of melatonin and melatonin derivatives: a patent review (2012 - 2014) 37
MT1-Selective Melatonin Receptor Ligands: Synthesis, Pharmacological Evaluation, and Molecular Dynamics Investigation of N-[[(3-O-Substituted)anilino]alkyl]amides. 36
Structure-based virtual screening of MT2 melatonin receptor: influence of template choice and structural refinement. 35
Kinetic analysis and molecular modeling of the inhibition mechanism of roneparstat (SST0001) on human heparanase 31
Totale 2.827
Salva come PNG Salva come JPEG
Categoria #
all - tutte 10.295
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 10.295
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020272 0 0 0 8 25 74 58 7 47 32 8 13
2020/2021146 4 9 11 10 10 10 11 7 41 13 12 8
2021/2022184 6 2 3 28 2 7 8 25 7 14 16 66
2022/2023891 99 107 39 60 103 97 14 48 299 2 21 2
2023/2024288 16 27 4 13 21 61 36 24 8 14 24 40
2024/2025158 26 64 61 7 0 0 0 0 0 0 0 0
Totale 2.827